The effect of dose on the pharmacokinetics of ciprofloxacin in serum and urine following single intravenous doses of 100, 150, and 200 mg was studied in nine healthy volunteers. Mean peak levels in serum were 1.4, 2.0, and 3.2 mg/liter for the 100-, 150-, and 200-mg doses, respectively. The data on concentrations in serum were best described by a three-compartment pharmacokinetic model. The terminal half-life (from noncompartmental analysis) averaged between 4.2 and 4.6 h. Average urinary recovery ranged between 45.8 and 48.1%. The average renal clearance of ciprofloxacin was 2.9-to 3.4-fold greater than the measured creatinine clearance. Total serum and renal clearances decreased with increasing dose; however, this was not statistically significant (P > 0.05; repeated-measures analysis of variance). Ciprofloxacin was well tolerated by all subjects. In this dose range, ciprofloxacin pharmacokinetics are independent of dose.
Ciprofloxacin is a new fluoroquinolone antibiotic with potent activity against many clinically important human pathogens (18) . As with several newer agents of this class, ciprofloxacin is well absorbed when administered orally and attains bactericidal concentrations in serum and many body fluids and tissues. The results of clinical trials with the oral formulation have documented the efficacy of this agent (1) ; studies with the parenteral formulation are in progress.
Nonlihear pharmacokinetic properties are often due to saturation of renal, hepatic, or other excretory pathways. This study was designed to characterize the excretion and distribution of ciprofloxacin following intravenous administration and to assess the effect of dose size on pharmacokinetic parameters. In addition, multicompartmental pharmacokinetic models were used to describe the pharmacokinetics of extravascular distribution of ciprofloxacin.
MATERIALS AND METHODS
Voluitteers. Nine healthy men were studied. The mean (± the standard deviation [ ceived three single, rising ciprofloxacin doses of 100, 150, and 200 mg at exactly 1-week intervals. Doses were prepared from ampoules containing 100 mg of ciprofloxacin (Miles Pharmaceuticals, West Haven, Conn.), which was diluted in normal saline to make a final volume of 100 ml. Each dose was infused over 30 min into a peripheral vein with a constant-rate infusion pump. Intravenous (i.v.) tubing and catheters were flushed with at least 25 ml of saline at the conclusion of the infusion to ensure complete delivery of the dose.
Blood was collected from a second indwelling intermittent i.v. infusion set (heparin lock) at the following times: predose (time zero) and 15 min (midinfusion), 30 min (end of infusion), 35, 40, and 50 min, and 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4.5, 6.5, 8.5, 10.5, 12.5, 16.5, 20.5, and 24.5 h after the start of the infusion. Serum was separated from cells by centrifugation, and aliquots were frozen. Urine samples were collected and pooled during 0 to 1.5, 1.5 to 2.5, 2.5 to 3.5, 3.5 to 4.5, 4.5 to 6.5, 6.5 to 8. The signal was recorded, and the peak height was determined with an integrator.
Stock solutions of ciprofloxacin (BAY 09867, lot 907337; Miles Pharmaceuticals) at 10 jxg/ml were prepared fresh daily in distilled water. Pipemidic acid (Sigma) at 100.0 and 5.0 ,ug/ml was prepared fresh daily in 1.0 N HCl and used as an internal standard at these concentrations for assay of urine and serum samples, respectively. Urine and serum standards were prepared fresh daily by using the stock solution of ciprofloxacin.
Standards and unknown serum samples were processed by pipetting 500 RI1 of serum into a 1-ml disposable syringe fitted with a 0.22-,um disposable filter (Duropore; Millipore). Fifty microliters of internal standard was added to a syringe, and the mixture was vortexed for 15 s. The filtrate was collected, and 10 j.I was injected into the instrument. Urine samples were prepared by vortexing thawed samples and diluting an aliquot with an appropriate volume of phosphate buffer to bring the concentration into the range of the standard curve. The column retention times for pipemidic acid and ciprofloxacin were 3.8 and 5.8 min, respectively. Peak heights were determined by the integrator, and ciprofloxacin peak height-internal standard peak height ratios were calculated; these ratios showed a direct linear correlation with the drug concentrations in known standards. Concentrations of unknown samples were calculated from the serum standard curves by least-squares regression. The sensitivity of the assay in serum was 0.008 mg/liter. Linearity of ciprofloxacin-internal standard peak height ratios was demonstrated with ciprofloxacin concentrations in serum and urine in the range of 0.01 to 1 and 0.1 to 20 mg/liter, respectively. Within-day precision for three serum standards ranging in concentration between 0.05 and 0.5 mg/liter (n = 5) was 2.4 to 5.2% (coefficient of variation). The accuracy (calculated as [actual measured]/actual x 100%) of these standards was +2.2 to 6.4%. Recovery of ciprofloxacin from serum was 96%. The ciprofloxacin serum standards were shown to be stable for at least 11 days at -70°C (data not shown).
Pharmacokinetic and statistical analyses. Data on concentrations in serum were analyzed by using compartmental and noncompartmental pharmacokinetic models. The areas under the zero and first moments of the concentration-time curves for serum were calculated by using the linear trapezoidal rule. The terminal slope (Xi) was identified by visual inspection of plots and calculated by using least-squares regression. Residual areas under the curve were determined by dividing the last detectable concentration in serum by X, (6) . Total-body clearance, volume of distribution at steady state, mean residence time, and noncompartmental half-life were calculated by using standard equations corrected for an i.v. infusion (6) . Renal clearance was calculated as the amount of drug excreted unchanged in urine during the urine collection interval divided by the area under the corresponding concentration-time curve for serum. The net renal secretion clearance of ciprofloxacin was calculated by renal clearance -(0.573 x measured creatinine clearance), where 0.573 is the fraction of ciprofloxacin unbound to serum protein measured in a previous study (8) .
Data on concentrations in serum were also analyzed by using two-and three-compartment open pharmacokinetic models by extended least-squares regression with an Applesoft version of the computer program MKMODEL (N. Holford, University of Auckland School of Medicine, Auckland, New Zealand, 1985), a variant of the program available on the PROPHET computer network (10, 11) . The variance in predicted concentrations was modeled as yPWR (power model), where PWR was constrained to be between 0 and 3. Macroscopic pharmacokinetic constants were used in defining pharmacokinetic models; standard equations were applied to correct for infusion time and calculate microscopic pharmacokinetic rate constants (6) . The goodness of fit of the two-or three-compartment body model to the data was determined by using the Schwartz criterion, defined as log likelihood -(K12 x ln N), where the log likelihood is computed by using the objective function of the extended least-squares regression and is a measurement of how well the parameters in the model describe the data, K is the total number of structural and variance model parameters, and N is the number of observations (13) .
The effect of dose on pharmacokinetic parameters was assessed by using analysis of variance for repeated measurements (12) . Noncompartmental pharmacokinetic analysis of data on concentrations in serum is summarized in Table 1 . Totalbody clearance and its two components, renal and nonrenal clearance, tended to decrease with increasing dose; however, this difference was not statistically significant (P > 0.05). The volume of distribution (steady state) of ciprofloxacin was large and averaged between 2.0 and 2.4 liters/kg, with no dose dependence (P > 0.05).
Urinary concentrations of ciprofloxacin and the excretion rate are depicted in Table 2 and Fig. 2 , respectively. Over 25% of the dose was excreted unchanged during the first 4 h. Concentrations in urine were high, with clinically significant concentrations still present at 48 h after the dose. The average urinary recovery of ciprofloxacin at 48 h ranged between 45.8 and 48.1% and was not dose dependent (Table  1 ; P > 0.05). On average, the renal clearance of ciprofloxacin was 2.9-to 3.4-fold greater than the measured creatinine clearance. The mean (±SD) net renal secretion clearance values were 3.83 (±1.10), 3.61 (±1.14), and 3.02 (±0.92) m/min per kg for the 100-, 150-, and 200-mg doses, respectively; the differences in these values were not statistically significant (P > 0.05).
Analysis of serum data with a three-compartment pharmacokinetic model is depicted in Table 3 . On the basis of the Schwartz criterion, most of the data sets were best described by using the three-compartment model; this was particularly true with the 200-mg dose. Two peripheral compartments and not dose dependent in the narrow dosage range studied, regardless of the type of pharmacokinetic analysis applied; this is similar to the conclusions reached in other studies of i.v. doses in this range (3, 5, 8, 9) . The values for total clearance of ciprofloxacin from serum for i.v. doses in the range reported here are in agreement with those reported by others (3, 7-9, 16, 17) but are higher than those calculated by Drusano et al. (5) .
Studies using radiolabeled drug have shown that ciprofloxacin is excreted unchanged in urine and feces and as four metabolites (2). Although not statistically significant, a trend toward decreasing clearance was observed in this study. Both nonrenal and renal ciprofloxacin clearances decreased with higher doses by approximately 15 to 20% with the higher dose. Saturation of nonrenal clearance may occur because of changes in the rate of hepatic biotransformation or decreased excretion into the gastrointestinal tract through biliary or other routes. Dose-ranging studies using large oral doses that might readily saturate hepatic metabolism during the first pass to the liver have not demonstrated changes with increasing dose (9, 15) . However, Drusano et al. were able to demonstrate a higher total clearance from serum, particularly of the nonrenal component, with a prolonged infusion of 200 mg over 4 h than with the same dose infused over 30 min (5) . Insufficient data exist to determine which of these mechanisms is responsible for the subtle changes in nonrenal clearance observed in these studies.
Renal excretion of ciprofloxacin is predominantly due to net renal tubular secretion of the drug. Although not statistically significant, a trend toward lower renal clearance values with increasing doses was observed in this study as in other studies (8, 9, 15) . This may be due to saturable renal tubular secretion of ciprofloxacin, as reflected in decreasing net renal tubular secretion clearance values (Table 1) .
Ciprofloxacin distribution to the extravascular space is extensive, as reflected by the large volume of distribution and high concentrations of ciprofloxacin in extravascular fluids and tissues (17, 18) . Our analysis with a threecompartmental pharmacokinetic model quantified the approximate sizes and the kinetics of distribution into two peripheral compartments. The rapidly equilibrating compartment (V2) has a high intercompartmental clearance rate; this accounts for the rapid decline in ciprofloxacin concentrations in serum immediately following the conclusion of drug infusion. A third, slowly equilibrating (or deep) tissue compartment with relatively slow intercompartmental clearance contributes to the prolonged terminal half-life (ca. 4 to 5 h) of ciprofloxacin.
Analysis of serum data by different pharmacokinetic methods has resulted in some confusion regarding estimates of some of the pharmacokinetic parameters (e.g., half-life) of the new fluoroquinolones. In contrast to previous studies, we performed our compartmental analysis by using extended least-squares regression, which has been demonstrated to be more precise and less biased in the estimation of pharmacokinetic parameters than other least-squares regression approaches (10, 14) . Extended least-squares regression analysis eliminates the necessity of choosing proper weights for analysis of data, which can greatly influence estimates of certain pharmacokinetic parameters (e.g., terminal half-life) whose estimation is largely based on drug concentrations measured in the lower range of assay sensitivity, where precision and accuracy are often poorest. In addition, the value of the terminal half-life may vary according to whether the analysis is conducted with a two-or three-compartment pharmacokinetic model. We used an objective method (the Schwartz criterion) as the basis for determining which model best described the data with the least number of structuralmodel parameters. This statistic is similar to the Akaike information criterion (19) ; however, it differs in its use of likelihood ratios rather than the sum of squares. Analysis demonstrated that the three-compartment model was superior to the two-compartment model in most data sets, primarily because of better precision in predicting concentrations in serum during hour 1 following the end of drug infusion. The superiority of the three-compartment model in describing the pharmacokinetics of ciprofloxacin following i.v. infusion has also been noted by others using different criteria (4, 5, 8) . However, despite the superiority of the three-compartment model in describing serum data, estimates of the major pharmacokinetic parameters (i.e., clearance, volume of distribution, and half-life) were similar with both methods, perhaps because of frequent sampling in the lower concentration ranges (i.e., the terminal slope).
In summary, we have demonstrated the linearity of ciprofloxacin pharmacokinetics in normal volunteers within the 100-to 200-mg dosage range following i.v. administration. Further studies using higher doses are needed to confirm linear pharmacokinetic properties with larger doses of this drug.
